Firalis creates novel values via biomarker discovery, development and regulatory qualification and brings to market biomarker-based diagnostic products. With a comprehensive expertise in the field, Firalis develops diagnostic kits and provides an extensive range of biomarker services; to improve therapeutic decisions as well as disease outcomes and patient comfort, finally to reduce healthcare costs at remarkable extents.
Activities of Firalis mainly but non-exclusively involve biomarkers of inflammatory disorders such as atherosclerosis, rheumatoid arthritis, rare/orphan diseases such as systemic or autoimmune vasculitis. A major part of our activities cover drug-induced organ injuries in particularly kidney, liver and vasculature, as major drug targets.
Firalis acquired its pioneering leadership in translational biomarkers to its unique network of clinicians and clinical centers of excellence that it built step by step, since 2008, thanks to many R&D consortia it coordinated, consisting partners from the European Academia (mostly University Hospitals), Big Pharma and other SME with complementary know-how. For numerous of its R&D projects, Firalis has been awarded with research and entrepreneurship awards as well as significant research grants which allowed us to conduct some of the largest clinical biomarker studies ever.
At Firalis, we exclusively invest on projects with highest potential of success, commercialize constantly new products, and target to launch a high-value in-vitro diagnostic kit of our own.